Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEITH A LERRO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1730161092
CMS profile
169870
Location
WILSON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$9,727.25

207 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,342.02 200
Consulting Fee $3,162.50 1
Honoraria $3,000.00 2
Education $222.73 4

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Global Blood Therapeutics, Inc. $3,217.83 5
G1 Therapeutics, Inc. $1,500.00 1
Pharmacosmos Therapeutics Inc. $1,500.00 1
Dendreon Pharmaceuticals LLC $209.83 10
Novartis Pharmaceuticals Corporation $193.38 12
AstraZeneca Pharmaceuticals LP $185.96 12
Amgen Inc. $177.93 7
PFIZER INC. $164.70 7
Daiichi Sankyo Inc. $159.11 11
Janssen Biotech, Inc. $153.41 10
GlaxoSmithKline, LLC. $149.70 5
Merck Sharp & Dohme Corporation $147.28 10
Coherus Biosciences Inc. $137.12 5
E.R. Squibb & Sons, L.L.C. $133.79 6
Genentech USA, Inc. $112.56 8
Incyte Corporation $110.33 7
GENZYME CORPORATION $98.23 6
Karyopharm Therapeutics Inc. $85.97 4
Lilly USA, LLC $80.27 4
Boehringer Ingelheim Pharmaceuticals, Inc. $80.19 4
AbbVie Inc. $70.14 4
Eisai Inc. $68.96 4
Gilead Sciences, Inc. $65.55 5
Exelixis Inc. $59.25 4
ASD SPECIALTY HEALTHCARE, LLC $58.04 1
Celgene Corporation $57.54 3
Seagen Inc. $51.90 4
Takeda Pharmaceuticals U.S.A., Inc. $45.31 2
Pharmacyclics LLC, An AbbVie Company $44.93 3
EMD Serono, Inc. $42.76 3
JAZZ PHARMACEUTICALS INC. $42.31 3
Myovant Sciences Inc. $42.30 3
Regeneron Healthcare Solutions, Inc. $35.80 2
Bayer HealthCare Pharmaceuticals Inc. $34.45 2
Organon LLC $34.10 3
Rigel Pharmaceuticals, Inc. $33.08 2
Servier Pharmaceuticals LLC $32.36 2
Janssen Pharmaceuticals, Inc $29.20 2
Kite Pharma, Inc. $27.42 2
Epizyme, Inc., $27.14 2
Acrotech Biopharma LLC $25.99 2
TG THERAPEUTICS, INC. $20.15 1
Dova Pharmaceuticals $18.72 1
Sobi, Inc $17.97 1
BeiGene USA, Inc. $17.05 1
PUMA BIOTECHNOLOGY, INC. $15.42 1
SANOFI-AVENTIS U.S. LLC $14.09 1
Secura Bio, Inc. $14.02 1
Horizon Therapeutics plc $13.96 1
Astellas Pharma US Inc $12.76 1
Blue Earth Diagnostics Limited $12.69 1
Alexion Pharmaceuticals, Inc. $12.42 1
TerSera Therapeutics LLC $12.10 1
Ipsen Biopharmaceuticals, Inc $11.54 1
ARRAY BIOPHARMA INC $8.24 1

Page 5 of 5; records 201–207 of 207 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEITH A LERRO

NPI 1730161092 · CMS profile ID 169870

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WILSON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–207 of 207 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730161092?year=2021&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEITH A LERRO, NPI 1730161092, CMS profile ID 169870. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–207 of 207 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730161092?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). KEITH A LERRO, NPI 1730161092, CMS profile ID 169870. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–207 of 207 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730161092?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
KEITH A LERRO, NPI 1730161092, CMS profile ID 169870, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–207 of 207 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1730161092?year=2021&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

207 matching records · $9,727.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 207 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–207 of 207.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $15.2101/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835936265 CMS
AbbVie Inc. $18.9601/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795298973 CMS
Myovant Sciences Inc. $14.9501/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834965457 CMS
AstraZeneca Pharmaceuticals LP $20.1101/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829486105 CMS
Daiichi Sankyo Inc. $14.9501/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836245861 CMS
AstraZeneca Pharmaceuticals LP $24.0901/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829925759 CMS
JAZZ PHARMACEUTICALS INC. $12.2301/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845577243 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34,315.17 231
PY2020 $4,384.74 174
PY2021 $9,727.25 207
PY2022 $7,162.75 221
PY2023 $10,263.73 220
PY2024 $9,068.39 214
PY2025 $4,640.33 188

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $421,529.93 32
PY2024 Recipient $1,386.05 1
PY2024 Principal investigator $357,799.31 10
PY2021 Principal investigator $3,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $7,410.00 12/22/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175336142
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 12/16/2025 Non-covered Recipient Entity
Sargon Research LLC
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220810320
Principal investigator 1 Novartis Pharmaceuticals Corporation $175.00 12/15/2025 Non-covered Recipient Entity
REGIONAL MEDICAL ONCOLOGY CENTER
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190313903
Principal investigator 1 Epizyme, Inc. $62.80 11/12/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282937
Principal investigator 1 Epizyme, Inc. $78.00 11/12/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282939
Principal investigator 1 PFIZER INC. $47,181.76 11/12/2025 Non-covered Recipient Entity
Regional Medical Onco Center
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228713154
Principal investigator 1 Exelixis Inc. $5,000.00 11/06/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384837
Principal investigator 1 Exelixis Inc. $2,000.00 11/06/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384839
Principal investigator 1 Exelixis Inc. $5,000.00 11/06/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384841
Principal investigator 1 Janssen Research & Development, LLC $12,854.00 11/03/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175336136
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $271.52 10/27/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998925
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 10/27/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998927
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.76 10/27/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998929
Principal investigator 1 PFIZER INC. $47,181.76 09/30/2025 Non-covered Recipient Entity
Regional Medical Onco Center
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228713336
Principal investigator 1 PFIZER INC. $47,181.76 09/02/2025 Non-covered Recipient Entity
Regional Medical Onco Center
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228713334
Principal investigator 1 Janssen Research & Development, LLC $21,836.00 09/01/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175336129
Principal investigator 1 AstraZeneca UK Limited $18,250.00 08/14/2025 Non-covered Recipient Entity
SARGON RESEARCH SUMMIT LLC
phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression No dispute reported 06/30/2026 1185555107
Principal investigator 1 Exelixis Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384833
Principal investigator 1 Exelixis Inc. $500.00 05/16/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384831
Principal investigator 1 Exelixis Inc. $500.00 05/16/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384835
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,500.00 03/07/2025 Non-covered Recipient Entity
Sargon Research LLC
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220810318
Principal investigator 1 Eli Lilly and Company $163,746.93 01/22/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187888242
Principal investigator 1 Exelixis Inc. $1,250.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384813
Principal investigator 1 Exelixis Inc. $1,000.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384815
Principal investigator 1 Exelixis Inc. $18,000.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384817
Principal investigator 1 Exelixis Inc. $1,500.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384821
Principal investigator 1 Exelixis Inc. $1,043.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384823
Principal investigator 1 Exelixis Inc. $3,000.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384825
Principal investigator 1 Exelixis Inc. $650.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384827
Principal investigator 1 Exelixis Inc. $900.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384829
Principal investigator 1 Eli Lilly and Company $1,028.76 01/09/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187887836
Principal investigator 1 Exelixis Inc. $1,500.00 01/03/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384819